Rossari Biotech logo

Rossari Biotech

ROSSARI NSE

Key Fundamentals

MicrocapSpecialty ChemicalsChemicals
Market Cap
₹2,457 Cr
Volatility
Low Risk
P/E Ratio
16.39
EBITDA
₹308 Cr
Return on Equity
11.19%
Debt to Equity
0.33
Book Value
₹240.7
EPS
₹24.68
52W High
₹690.3
52W Low
₹375

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company's working capital requirements have reduced from 62.4 days to 48.6 days

Weaknesses

2
  • Company has a low return on equity of 12.0% over last 3 years.
  • Dividend payout has been low at 2.00% of profits over last 3 years

Growth Rate

Revenue Growth
16.04% higher than 3Y
Net Income Growth
9.38% higher than 3Y
Cash Flow Change
-52.66% lower than 3Y
ROE
-2.7% lower than 3Y
ROCE
3.22% higher than 3Y
EBITDA Margin (Avg.)
-1.24% higher than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 69d ago
AI opinion · based on fundamentals
Risk high

Rossari Biotech trades at a market cap of ₹2,970 Cr with a PE of 19.4x and has delivered 5-year sales CAGR of 28%, though profitability growth has lagged at 11% CAGR over the same period. The stock has underperformed significantly with a 1-year return of -24% and 3-year CAGR of -16%, while ROE remains modest at 11-12%.

Bull Case 7
  • Strong 5-year compounded sales growth of 28% indicates robust top-line expansion and market share gains in specialty chemicals
  • TTM revenue growth of 15% shows continued momentum in sales despite broader market headwinds
  • Working capital days improved significantly from 62.4 days to 48.6 days, freeing up cash and improving capital efficiency
  • PE of 19.4x is reasonable for a specialty chemicals company with double-digit sales growth, suggesting valuation is not stretched
  • Price-to-book of 2.17x is modest relative to the 5-year compounded sales growth of 28%, indicating potential value if growth sustains
  • 5-year compounded profit growth of 11% demonstrates the company has been able to scale profitability alongside revenue growth over the medium term
  • Stock decline of -24% over 1 year and -16% CAGR over 3 years means the stock is trading well below its historical highs, compressing valuation multiples
Bear Case 8
  • Stock has delivered -24% return over 1 year and -16% CAGR over 3 years, reflecting sustained negative market sentiment
  • TTM profit growth is -1%, indicating margin compression and inability to convert revenue growth into bottom-line expansion
  • 3-year ROE of only 12% is low for a specialty chemicals company, suggesting suboptimal capital allocation
  • Wide gap between 5-year sales CAGR of 28% and profit CAGR of 11% signals deteriorating operating leverage or rising input costs eating into margins
  • Dividend payout of only 2% of profits over the last 3 years provides negligible shareholder returns, with dividend yield at just 0.1%
  • Last year ROE dropped to 11% from the 5-year average of 13%, showing a declining return trend on equity deployed
  • 5-year stock CAGR of -15% despite 28% sales CAGR suggests the market is pricing in structural concerns about profitability sustainability
  • 3-year profit CAGR of only 8% compared to 13% sales CAGR over the same period shows persistent margin headwinds

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 69d ago
Positives 2
  • Scope 1 emissions cut 37% Jun 29

    Rossari Biotech reduced Scope 1 emissions by 37.25% in FY26, driven by lower diesel consumption. Energy and water intensity also improved alongside increased waste recycling.

  • Thailand facility goes live Jun 26

    Subsidiary Unistar Thai established a blending facility in Thailand with 5000 MTPA capacity to serve the Southeast Asian market.

Neutral 2
  • Record date for dividend fixed Jun 18

    Record date set for July 10, 2026 for dividend payment. 17th AGM scheduled for July 20, 2026.

  • Investor meet scheduled Jun 8

    Virtual investor and analyst meet held on June 12, 2026 to discuss public financial information.

TL;DR: Rossari Biotech is making progress on sustainability with a significant 37% cut in Scope 1 emissions and expanding its international footprint via a new Thailand blending facility. No material headwinds emerged in the recent news cycle. The trend appears constructive with geographic diversification into Southeast Asia and improving ESG metrics, though investors should watch for revenue growth and margin updates at upcoming meets.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
411
483
464
473
490
498
513
580
544
586
582
685
697
Expenses
353
420
400
409
425
432
448
510
476
514
513
608
617
Operating Profit
58
64
64
64
65
66
65
69
68
72
69
77
81
OPM %
14%
13%
14%
13%
13%
13%
13%
12%
12%
12%
12%
11%
12%
Other Income
2
1
4
1
1
1
1
2
2
2
1
20
4
Interest
6
5
4
3
4
4
5
6
6
6
8
9
11
Depreciation
14
15
15
16
15
15
18
18
18
18
20
24
26
PBT
39
45
48
46
47
48
42
48
46
50
43
64
48
Tax %
26%
26%
28%
25%
26%
27%
25%
28%
27%
26%
23%
28%
26%
Net Profit
29
33
34
34
35
35
32
34
34
37
33
46
35
EPS in Rs
5.3
5.97
6.23
6.18
6.32
6.39
5.73
6.22
6.07
6.66
5.92
8.3
6.34
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
516
600
709
1,483
1,656
1,831
2,080
2,396
2,550
Expenses
438
495
586
1,299
1,433
1,581
1,815
2,110
2,251
Operating Profit
78
105
124
184
223
250
265
286
299
OPM %
15%
17%
17%
12%
13%
14%
13%
12%
12%
Other Income
1
4
9
13
6
8
5
24
26
Interest
3
4
3
13
22
19
18
29
34
Depreciation
12
17
23
48
63
60
67
79
87
PBT
63
88
107
136
144
178
185
203
204
Tax %
28%
26%
25%
28%
26%
26%
26%
26%
—
Net Profit
46
65
80
98
107
131
136
149
151
EPS in Rs
104
12.86
15.45
17.74
19.45
23.66
24.63
26.94
27.22
Div. Payout %
0%
4%
3%
3%
3%
2%
2%
2%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
4
10
10
11
11
11
11
11
Reserves
119
277
398
794
904
1,037
1,174
1,322
Borrowings
8
67
0
8
74
119
218
436
Other Liabilities
118
118
152
442
375
401
482
505
Total Liabilities
250
471
561
1,255
1,364
1,567
1,886
2,274
Fixed Assets
74
94
181
607
585
578
598
784
CWIP
3
22
0
1
16
47
140
173
Investments
0
18
0
36
51
63
84
62
Other Assets
173
338
379
611
712
880
1,063
1,254
Total Assets
250
471
561
1,255
1,364
1,567
1,886
2,274
Figures in ₹ Crores

Cash Flow

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
71
57
48
29
152
43
137
65
Investing
-37
-190
-37
-299
-181
-103
-183
-220
Financing
-29
157
-25
292
61
16
65
186
Net Cash Flow
5
23
-14
22
32
-44
19
31
Free Cash Flow
27
-19
-8
-7
120
-83
-21
-175
CFO/OP
118
74
64
43
89
39
74
47
Figures in ₹ Crores

Ratios

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
61
57
74
75
78
85
83
85
Inventory Days
59
57
75
63
59
80
90
88
Days Payable
114
95
104
61
56
62
73
71
Cash Conversion Cycle
6
19
46
76
80
103
101
103
Working Capital Days
23
22
60
62
49
70
69
49
ROCE %
—
38%
29%
24%
18%
18%
16%
13%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Rossari Biotech insights

63 extracted metrics + investor summaries across FY19–FY27.

Log in — free

Shareholding Pattern

Others1.80%Promot.68.14%FIIs2.02%Public13.39%DIIs14.64%As ofJun 2026

Documents

Frequently Asked Questions about Rossari Biotech

What does Rossari Biotech Ltd do?
Rossari Biotech was started in 2003. They are among the largest manufacturers of textile specialty chemicals in India.[1]
Where is Rossari Biotech Ltd (ROSSARI) listed?
Rossari Biotech Ltd trades as ROSSARI on the NSE and under code 543213 on the BSE.
Which sector does Rossari Biotech Ltd belong to?
Rossari Biotech Ltd is classified under the Chemicals sector, in the Specialty Chemicals industry.
What is the market capitalisation of Rossari Biotech Ltd?
Rossari Biotech Ltd has a market capitalisation of ₹2,457 Cr, which places it in the Small Cap band.
What is the PE ratio of Rossari Biotech Ltd?
Rossari Biotech Ltd trades at a PE ratio of 16.39, on earnings per share of ₹24.68, against a book value of ₹240.7 per share.
What is the 52-week high and low of Rossari Biotech Ltd?
Over the last 52 weeks Rossari Biotech Ltd has traded between ₹375 and ₹690.3.
Does Rossari Biotech Ltd pay dividends?
Rossari Biotech Ltd has a dividend yield of 0.11%.
What is the Return on Equity (ROE) of Rossari Biotech Ltd?
Rossari Biotech Ltd reported a return on equity of 11.19%. Its debt-to-equity ratio is 0.33.

Company Information

Rossari Biotech was started in 2003. They are among the largest manufacturers of textile specialty chemicals in India.[1]

Website rossari.com
Listed 2020-07-23
Face Value ₹ 2
Issued Size 5,53,81,366

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ROSSARI.md for Rossari Biotech Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Chemicals → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List